These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

310 related articles for article (PubMed ID: 2811008)

  • 1. [Evaluation of clinical efficacy of isoniazid and ethambutol in the treatment of nontuberculous mycobacteriosis based on in vitro susceptibility testing].
    Tsukamura M
    Kekkaku; 1989 Aug; 64(8):511-8. PubMed ID: 2811008
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Sulfadimethoxine as a promising drug in the treatment of infections caused by Mycobacterium kansasii and Mycobacterium xenopi--differentiation between M. kansasii and M. marinum and between M. gordonae and M. scrofulaceum by the susceptibility testing to sulfadimethoxine].
    Tsukamura M
    Kekkaku; 1989 Apr; 64(4):313-7. PubMed ID: 2747117
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [In vitro susceptibility testing of nontuberculous mycobacteria to streptomycin, kanamycin and enviomycin].
    Tsukamura M
    Kekkaku; 1989 Sep; 64(9):557-62. PubMed ID: 2554046
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Chemotherapeutic regimens for nontuberculous mycobacterial infection based on in-vitro susceptibility test results].
    Tsukamura M; Yamori S
    Kekkaku; 1990 May; 65(5):349-57. PubMed ID: 2168003
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Evaluation of clinical efficacy of rifampicin in the treatment of nontuberculous mycobacteriosis from in vitro susceptibility testing].
    Tsukamura M
    Kekkaku; 1989 Jul; 64(7):453-8. PubMed ID: 2585946
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Differentiation between Mycobacterium malmoense and Mycobacterium nonchromogenicum by ethambutol susceptibility].
    Yamori S; Tsukamura M
    Kekkaku; 1989 Feb; 64(2):95-7. PubMed ID: 2733305
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Antimycobacterial susceptibility against nontuberculous mycobacteria using brothmic NTM].
    Kawata N; Kawahara S; Tada A; Takigawa N; Shibayama T; Soda R; Takahashi K
    Kekkaku; 2006 Apr; 81(4):329-35. PubMed ID: 16715941
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Evaluation of cycloserine in the treatment of infections caused by nontuberculous mycobacteria viewed from in vitro experiments].
    Tsukamura M
    Kekkaku; 1989 May; 64(5):345-9. PubMed ID: 2507817
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Clinicopathological study of cases with Mycobacterium szulgai infection].
    Iwanaga T; Kishikawa R; Ikeda T; Hirose T; Tsurutani H; Yoshida S
    Kekkaku; 1998 Oct; 73(10):579-84. PubMed ID: 9844345
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Clinical studies on lung disease caused by atypical mycobacteria in our hospital--especially in relation to drug susceptibility].
    Mineshita M; Miyazawa T; Doi M; Suei S; Matsuura M; Senoo T; Yamakido M
    Kekkaku; 1993 Jul; 68(7):479-86. PubMed ID: 8361116
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Current treatment of atypical mycobacteriosis.
    Esteban J; Ortiz-Pérez A
    Expert Opin Pharmacother; 2009 Dec; 10(17):2787-99. PubMed ID: 19929702
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nontuberculous mycobacteria: susceptibility pattern and prevalence rate in Shanghai from 2005 to 2008.
    Wang HX; Yue J; Han M; Yang JH; Gao RL; Jing LJ; Yang SS; Zhao YL
    Chin Med J (Engl); 2010 Jan; 123(2):184-7. PubMed ID: 20137367
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Combination of gentamycin and amikacin with rifampicin, ethambutol and isoniazid on selected standard strains of Mycobacterium species in experiments done in vitro and in vivo].
    Janowiec M; Andrzejczyk Z; Marczewska J
    Pneumonol Pol; 1989 May; 57(5):300-7. PubMed ID: 2633149
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Evaluation of a newly developed broth microdilution test method to determine minimum inhibitory concentrations (MICs) of antimicrobial agents for mycobacteria].
    Yamane N; Nakasone I; Saitoh H; Kaneda M; Shimojima M; Yamashita K; Toyoda K; Okazawa Y
    Rinsho Byori; 1998 Jul; 46(7):719-27. PubMed ID: 9721542
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [A case of pulmonary infectious disease due to Mycobacterium szulgai].
    Kobashi Y; Okimoto N; Soejima R
    Kekkaku; 1999 Oct; 74(10):715-9. PubMed ID: 10565131
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mycobacterium resistance to antimycobacterial reagent.
    Aghandous R; Zouhdi M; Zizi M; Errami M; Idrissi L
    Therapie; 1999; 54(5):623-5. PubMed ID: 10667100
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Two cases of Mycobacterium szulgai pulmonary disease in the elderly].
    Hamada M; Kajiki A; Nagata N; Wakamatsu K; Komori M; Matsunaga K; Iwata Y; Ishimatsu A; Kitahara Y
    Kekkaku; 2005 May; 80(5):427-32. PubMed ID: 16083051
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Utility of the direct culture examination (Ziehl-Neelsen) using the Bactec system for the presumptive identification of Mycobacterium tuberculosis complex, Mycobacterium avium complex, Mycobacterium xenopi, and Mycobacterium kansasii].
    Moreno C; Garrigó M; Sánchez F; Coll P
    Enferm Infecc Microbiol Clin; 1994 May; 12(5):241-5. PubMed ID: 7811323
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Resistance behavior of atypical mycobacteria to antibiotics and sulfonamides].
    Neubert R
    Z Erkr Atmungsorgane; 1986; 167(1-2):47-51. PubMed ID: 3765715
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Nontuberculous mycobacteria and incidence of mycobacterioses in Prague in 1999-2004].
    Polanecký V; Kalina P; Kubín M; Kozáková B; Müllerová M
    Epidemiol Mikrobiol Imunol; 2006 Nov; 55(4):151-7. PubMed ID: 17354590
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.